



LEPROSY RESEARCH INITIATIVE



ANNUAL REPORT 2023

2 CONTENTS

3	Foreword	3
4	About the Leprosy Research Initiative	4
5	Promoting, facilitating and funding high-quality leprosy research	5
5.1	Regular Grant cycle in 2023	5
5.2	Start of research projects	6
5.3	Monitoring of ongoing research projects	6
5.4	Geographical distribution research projects	7
5.5	Completed projects	7
5.6	New Grant: RESILIENTD	7
6	Strengthening research capacity	8
6.1	LRI Spring Meeting – in-person event	8
6.2	Online highlights of LRI Spring Meeting event	8
6.3	Research capacity strengthening grant	9
6.2	Workshop on scientific writing	9
7	Facilitating translation of research results into policy and practice	10
7.1	Impact Assessment	10
7.2	Communications	10
8	Celebrating 10 years Lri	11
9	Future perspectives	12
10	Our partners in 2023	13
11	Our team in 2023	13
11.1	Executives Group	13
11.2	Steering Committee	13
11.3	Scientific Review Committee	14
11.4	LRI Communications Committee (COCO)	14
11.5	LRI Secretariat	14
12	Reviewer acknowledgements	15
13	Financial narrative	16
14	Annual accounts	17
	Colophon	34

3 FOREWORD

We look back on a special anniversary year for LRI, as it has been 10 years since its founding in 2013. It was a pleasure to celebrate this milestone with many of you during several activities throughout the year. To reflect on the achievements of the work of LRI during the past decade, we conducted a research funding impact assessment, which has provided us with insights and recommendations to improve supporting, monitoring and sharing impact. We also increased our communication efforts to better inform stakeholders on LRI's work.

In 2023, we supported 39 research projects in 22 countries across our five research priorities of diagnostics tests, disability, operational research, stigma & discrimination and transmission. For these projects, including eight which started during 2023, a total of €1,145,144 was allocated throughout the year and we commend the research groups for the great progress they made in their projects. At the end of the year, we awarded seven new grants to promising research projects.

We were also very excited to have awarded two research capacity strengthening grants for the first time in 2023. In addition, we are pleased to have intensified our partnership with Anesvad Foundation, launching a new research grant focusing on social determinants of health in the context of skin-NTDs.

The LRI Spring Meeting was organised in-person again, bringing together over 80 participants from 20 countries, which has been a great platform to meet each other and discuss advancements in leprosy research. In addition, we held an online 'Highlights of Spring Meeting' event, welcoming a further 100 participants.

Towards the end of the year, we started the development of blended training opportunities and look forward to hosting our first blended LRI research course on scientific writing in 2024.

We wish to thank everyone who contributed to the work of LRI in 2023 through personal involvement, organisational support or collaboration in our shared aim towards zero leprosy.



Linda Hummel

Director

4 ABOUT THE LEPROSY RESEARCH INITIATIVE

The Leprosy Research Initiative (LRI) was launched in 2013 to boost scientific research in leprosy.

Our vision is a **world free of leprosy** and we aim to contribute to this vision by:

1. promoting, facilitating and funding high-quality leprosy research;
2. strengthening research capacity in endemic countries, and;
3. facilitating translation of research results into policy and practice.

An established joint research fund combined with an efficient, transparent and rigorous selection and progress monitoring processes ensure scientifically high-quality and sustainable funding. Understanding training needs and providing opportunities for shared learning strengthen capacity in research. Through encouragement and monitoring of dissemination and uptake of study findings, we strive for a positive impact towards zero transmission, zero disability and zero exclusion.

The LRI is governed and managed by the following bodies:

Executives Group (EG): oversees strategy and is the decision-making authority; consists of the executive directors of the LRI Full Partners.

Steering Committee (SC): provides scientific guidance and reviews submitted letters of intent; consists of the research coordinators of the LRI Partners and an independent Chair.

Scientific Review Committee (SRC): assesses full proposals and project progress; consists of independent scientists.

Secretariat: provides grant management and administration, technical support, and partner management; facilitates capacity strengthening, communication, meetings and events; based in Amsterdam, the Netherlands.

Following a priority-setting assessment, LRI stakeholders identified five main research priorities for 2020-2025:

- **1. Diagnostic tests**
To develop and test new assays for diagnosis of disease and infection.
- **2. Disability**
To promote prevention, early detection and effective treatment of nerve function impairment and reactions / improve the coverage of prevention of disability activities and their integration in appropriate programmes.
- **3. Operational research**
To improve the efficiency, effectiveness, or reach of available tools, in order to improve health programs and health outcomes.
- **4. Stigma & discrimination**
To reduce stigma as a barrier to zero leprosy and to improve mental wellbeing of persons affected and their families.
- **5. Transmission**
Implementation research on post-exposure prophylaxis and leprosy vaccine studies which have reached the stage of human trials. Basic research including susceptibility for *M leprae*, clinical progression, non-human reservoirs, genetic epidemiology.

To be eligible for LRI funding, projects should focus on one of these priorities. More details can be found in our [LRI Joint Research Policy 2020-2025](#).

5 PROMOTING, FACILITATING AND FUNDING HIGH-QUALITY LEPROSY RESEARCH

The annual regular call for research proposals consists of a two-stage application process; the submission of an initial Letter of Intent (LoI) outlining the study aim, envisaged approach and indication of scope, budget and timeline, followed by a detailed proposal for selected applicants. We have developed a thorough review process using an online grant management system, that gives applicants the opportunity to improve their application based on the feedback from external reviewers resulting in the selection of the most promising proposals for high-quality and impactful leprosy research.

5.1 REGULAR GRANT CYCLE IN 2023

The submission and review process of applications started with the launching of the call for proposals in December 2022 (step 1), with a special focus on research on transmission.

After closing the submission deadline in January 2023, the Steering Committee (SC) met virtually in March to discuss their review of the LoIs (step 2). Selected applicants were invited to submit a full proposal (step 3), these were reviewed by external reviewers (step 4).

Their anonymous feedback was shared with the applicants which could be addressed in the rebuttal proposal (step 5).

Next, in Autumn meetings, the Scientific Review Committee (SRC) reviewed the rebuttal proposals and recommended a selection of projects for funding, further discussed and ranked by the SC (step 6).

The final decision to accept proposals for funding was made by the Executives Group (EG) in November (step 7) after which the research groups were informed.



5.2 START OF RESEARCH PROJECTS

In addition, eight research projects made their start in 2023 – with a total budget of €886,118. These grants had been awarded at the end of 2022, selected from 62 Letters of Intent out of which 18 full proposals (29%) were reviewed. The newly started projects were:

Title	Lead applicant <i>Host institution</i>	Country	Budget	Co-funding
			Duration	
Compassion training for reducing stigma and improving quality of care for persons affected by leprosy.	Agarwal <i>NLR India Foundation</i>	India	€107,272	
			24 months	
Setting an external quality assessment (EQA) programme for enhancing capacity building focusing to the microbiological tools used in the diagnosis of leprosy and the detection of drug resistance.	Cambau <i>French National reference center for mycobacteria</i>	France	€60,000	
			24 months	
Addressing healing after multi-drug treatment centred around perspectives of persons affected by leprosy, their families and healthcare providers: a qualitative study.	Darlong <i>TLM Trust India</i>	India	€82,695	
			27 months	
The role of persons affected as agents of change in their community: leprosy peer mentors to support case detection, DMDI and stigma reduction.	Edmiston <i>ALM</i>	Ghana	€100,166	St. Francis Leprosy Guild
			30 months	
Evaluation of <i>M. leprae</i> specific RPA assay incorporated in mobile suitcase lab for rapid diagnosis of clinical and sub-clinical Leprosy in Bangladesh.	Hossain <i>icddr,b</i>	Bangladesh	€60,000	Turing Foundation
			18 months	
Personalised footwear for foot ulcers in leprosy by baropodometry through an innovative community engagement model.	Pallapati <i>LEPRA Society</i>	India	€118,675	
			18 months	
Leprosy incidence, clustering and risk factors: Evidence from 5-year follow-up trial Maltalep and Ideal study in Bangladesh.	Saha <i>Erasmus MC</i>	Bangladesh	€47,680	Turing Foundation
			12 months	
Evaluation of five transcriptomic biomarkers for leprosy in a Colombian population.	Serrano-Coll <i>Instituto Colombiano de Medicina Tropical - Universidad CES</i>	Colombia	€309,630	Turing Foundation
			48 months	

5.3 MONITORING OF ONGOING RESEARCH PROJECTS

Grantees submit progress reports twice a year, in March and September, on the basis of which the progress of the [funded projects](#) is monitored.

The SRC assesses study progress and financial reporting and discusses these in their in-person Spring meeting (April 2023) and virtual Autumn meeting (October 2023), after which they provide


recommendations to the EG on continuation of funding.

About a quarter of projects requested a no-cost extension, mainly due to unexpected delays such as ethical approvals and working through pandemic-related backlog. After SRC review, all requested extensions were accepted by the EG.

5.4 GEOGRAPHICAL DISTRIBUTION RESEARCH PROJECTS

The 39 LRI-funded projects active in 2023 were carried out in 22 countries across several continents. Multiple projects are ongoing in India (9), Nepal (6), Bangladesh (5), Indonesia (5), Nigeria (4), Brazil (4), and Ghana (2), and seven

studies are conducted in more than one country. Noteworthy is that India, Brazil and Indonesia combined account for over 75% of newly diagnosed leprosy cases globally.



5.5 COMPLETED PROJECTS

The following projects have been successfully completed in 2023:

- 707.19.57: [PEOPLE: Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar](#)
- 707.19.02: [Monitoring the effect of prophylactic interventions in contacts of leprosy patients including field-application of a novel immunodiagnostic test in Bangladesh](#)
- 707.19.62: [Integrated approach with skin camp, eSkin Health app, and tele-dermatology in early detection and effective management of skin NTDs in Côte d'Ivoire](#)

5.6 NEW GRANT: RESILIENTD

In collaboration with Anesvad Foundation, a new call for proposals was launched in December 2023: the RESILIENTD grant, with a special focus on social determinants of skin NTDs in Sub-Saharan Africa. The acronym for 'REsearch on SociaL determinants of LEprosy and NTDs' reflects the resilience of communities affected by skin NTDs and resilience of researchers, donors and the wider public health stakeholders to eliminate NTDs.

The RESILIENTD grant is facilitated by the LRI Secretariat, supported by LRI structures and funded by Anesvad Foundation. We gratefully acknowledge this strengthened partnership for increased efforts on this important research topic. Initial large interest highlights the need for funding and we look forward to award the first grants to promising projects in December 2024.



6 STRENGTHENING RESEARCH CAPACITY

An important objective of LRI is to strengthen capacity of researchers and organisations, with a focus on those based in leprosy-endemic countries and early career researchers. Several activities in 2023 were organised with the aim to contribute to expanding research knowledge, skills and experience.

6.1 LRI SPRING MEETING – IN-PERSON EVENT

The Eighth annual LRI Spring Meeting was held on 20-21 April 2023 in Breukelen, the Netherlands. The event brought together over 80 attendees from 20 countries, including LRI-funded researchers, LRI committee members and Partners, and others with a particular interest in leprosy research.

During the Spring Meeting, the progress and results from ongoing LRI-funded research projects are presented and discussed, and the event is a platform for shared learning and networking.

In total, 31 progress presentations were given on ongoing projects covering all five LRI research priorities and the R2STOP Initiative presented key

outcomes of their funded projects. On Friday afternoon, participants attended thematic sessions on topics of their preference including transmission, research capacity strengthening, and mental wellbeing, all sparking lively discussions.

After several years without an in-person Spring Meeting, participants expressed their appreciation for being able to meet together again. As Dr. Richard Truman, Chair of the LRI SRC said: *"this year's Spring Meeting was a resounding success, showcasing high-quality presentations and encouraging scholarly, social, and personal interactions among individuals in the leprosy world"*.



6.2 ONLINE HIGHLIGHTS OF LRI SPRING MEETING EVENT

LRI also hosted an online 'Highlights of LRI Spring Meeting' event on the 1st of June. During the event, six selected project progress presentations from the in-person Spring Meeting were showcased, covering a wide range of diverse research priorities, project countries and researchers.

The event was open to everyone with an interest in leprosy research and participation was free-of-charge. This virtual gathering aimed to provide an opportunity for global participation. Over 110 participants joined from all around the world, highly

valuing the opportunity to learn about a range of leprosy research and LRI's projects, as indicated by their survey feedback. A substantial portion of the online attendees (57%) had not previously participated in an LRI Spring Meeting, indicating the event's ability to attract new audiences.

In 2024, we look forward to hosting the Spring Meeting in-person as well as a Highlights of Spring Meeting event online, providing a platform for sharing research findings and facilitating connections in research.

6.3 RESEARCH CAPACITY STRENGTHENING GRANT

The Research capacity strengthening grant call was launched for the first time in December 2022. This grant specifically focuses on capacity strengthening of early career leprosy researchers across the five LRI priority areas.

The call received great interest with 48 Letters of Intent being submitted and six being invited to submit a Full Proposal.

Following review, two early career researchers were awarded the Research capacity strengthening grant in June and started their projects.

We thank the LRI SC, SRC and EG for their additional support and efforts to review, select and award these grants and look forward to the successful implementation of these projects and the continued support to strengthening research capacity.

Title	Lead applicant Host institution	Country	Budget	Duration
Collaborative co-design to optimize evidence-based and contextual general health worker training in integrated screening for leprosy and other skin NTDs in Nigeria.	Dr Suleiman Hudu Abdullahi <i>RedAid Nigeria</i>	Nigeria	€20,000	24 months
Thermographic assessment of autonomic innervation in leprosy.	Dr Suraj Maharjan <i>International Nepal Fellowship Green Pastures Hospital</i>	Nepal	€19,750	24 months

6.2 WORKSHOP ON SCIENTIFIC WRITING

Following the most recent LRI workshop on Data analysis in Nepal in 2022, the next workshop will focus on scientific writing. This topic was recommended by the Steering Committee as well as through the impact assessment and aims to strengthen capacity on writing a scientific paper for publication in a peer-reviewed journal.

In addition, several researchers have expressed interest in a blended training programme, with the in-person component organised in combination with a set event. Therefore, in the last quarter of 2023, we collaborated with the Lift Leprosy Learning project, NLR, KNCVTB+ and Health[e]Foundation to develop an e-course on scientific writing, which will be hosted on the e-learning platform of InfoNTD.

These modules will give participants from selected LRI-funded projects in advanced stages of their research the context in preparation for the in-person 4-day workshop which will be adjacent to the LRI Spring Meeting. There, they will progress on their paper under the guidance of experienced mentors.

We hope this initiative will boost sharing of research findings and build towards a more sustainable training environment for early career researchers of LRI-funded projects.

e-learning.infoNTD.org
your NTD interactive learning platform


LEPROSY RESEARCH INITIATIVE

 until
No Leprosy Remains

KNCV
TB | PLUS

HEALTH [e] FOUNDATION

7 FACILITATING TRANSLATION OF RESEARCH RESULTS INTO POLICY AND PRACTICE

LRI considers it important that research results are applicable to interrupt transmission, improve leprosy services or contribute to the wellbeing of persons affected by leprosy. In order to achieve such impact we encourage researchers to involve stakeholders in the research development and implementation process and in the dissemination of findings to optimise uptake.

7.1 IMPACT ASSESSMENT

In 2023, a research impact assessment was undertaken to better understand projects' impact and identify facilitators and barriers towards stronger impact.


Data from final reports of 41 completed projects, as well as surveys and interviews among the PIs of these projects were collected and analysed.

The findings of the assessment established that LRI-funded research projects have made numerous impacts in all categories of impact including; research-related, policy-related, health-related, and societal-related. Furthermore, impacts were found at (sub-)national and international levels.

Identified barriers and facilitators in generating impact were mostly regarding the collaboration within the research team and partners, with external stakeholders (eg policy makers) as well as societal or context-related factors such as involving the community throughout the research process.

The assessment also yielded several valuable recommendations for enhancing supporting, monitoring, and sharing the impact of LRI-funded projects in the coming years, which will be taken forward. These included developing a guidance for researchers, revising how we capture impact during the project and after completion, and new ways to regularly share research findings with stakeholders.

The study's findings were presented at the ECTMIH Conference in the Netherlands in November.



7.2 COMMUNICATIONS

Project publications were reported by the research groups through progress reports and by email, and subsequently added to the LRI website.

In 2023, we had more than 9,620 visitors to the LRI website. Several newsletters have been sent throughout the year, informing our >1,400 contact subscribers about the latest LRI news and updates.

Also, a new LRI Communications Committee (COCO) was formed, bringing together communication representatives from our Full Partner organisations for quarterly discussions on

LRI communications matters. With their guidance and expertise we are strengthening our communications and keep our audiences informed about research findings, achievements, opportunities, and new developments.

Together with COCO, we also launched an LRI [LinkedIn account](#). Through this platform, we disseminate LRI updates and engage a network of people committed to eliminating leprosy. Since the launch of the channel in September, it has gathered over 400 followers, a number we aim to grow further in 2024.

8 CELEBRATING 10 YEARS LRI

On the 17th of September 2013, LRI was launched at the 18th International Leprosy Congress in Brussels. In 2023, we marked a decade of active operation, having provided funding for over 80 projects in more than 20 countries and organising activities to strengthen research capacity. These projects have received a total allocation of over €10 million.

In light of this major milestone, we organised several celebratory activities to commemorate the special occasion:

- A [short animated video](#) was created spotlighting LRI's major achievements over the years.
- A special anniversary logo was created and featured on LRI's website and in the Secretariat's email signatures.
- We launched our new LinkedIn channel on our anniversary day
- The in-person Spring Meeting and online Highlights event featured a special anniversary session
- LRI Committee members were gratefully acknowledged at the Spring Meeting
- All those subscribed received a celebratory LRI newsletter
- Several researchers, (collaborating) partners of LRI, and committee members shared [celebratory messages](#) to commemorate the anniversary.

We extend our heartfelt gratitude to all those who have contributed to LRI throughout these years!




“

It is my pleasure to pay tribute to LRI for its many fine achievements over the last ten years. Three things of note stand out for me: Firstly, I believe the LRI has helped galvanise research and bring researchers closer together within the global leprosy community. A second achievement has been the capacity building workshops which has helped better equip researchers working in leprosy. Thirdly, extending calls for proposals from new researchers has given this group a great opportunity to gain valuable experience.

I wish everyone associated with the LRI my warm congratulations on reaching this important milestone.

”

Brent Morgan
International Director |
The Leprosy Mission International




“

One never ceases to learn – this is especially true for neglected tropical diseases such as leprosy.

In the case of leprosy in particular, new findings constantly emerge, changing the way we deal with the "world's oldest disease". For example, we are currently exploring optimal methods for raising awareness about leprosy and for active case-finding in communities. Furthermore, we are investigating the extent to which drug-resistance is already appearing against the leprosy medication. Also, we are researching the impact of leprosy disease on mental health.

Through its support, LRI makes an important contribution to the continued scientific study of a disease that we have already been able to significantly curb in the same manner. We are confident that in the future these efforts will continue to succeed.

”

Dr. Christa Kasang
Research Coordinator of DAHW
Member of LRI Steering Committee



9 FUTURE PERSPECTIVES

During December 2023, the funding allocations for successful proposals were decided, new calls for proposals were launched and the annual plan for 2024 was agreed.

Seven newly awarded research projects will start and for 39 ongoing projects, progress will be monitored. The submitted Letters of Intent will be reviewed after which the strongest selection moves forward.

The new RESILIENTD call for proposals has sparked interest from many research groups across skin-NTDs, we look forward to awarding the first grants to promising researchers at the end of the year.

The LRI Spring Meeting will be held in-person in the Netherlands in April 2024, bringing together researchers from the funded projects, LRI committees' members and other stakeholders. The online 'Highlights of the Spring Meeting' event will be organised a few weeks later for a wider audience.

Following the Spring Meeting, we organise the scientific writing workshop to strengthen scientific writing capacity and encourage dissemination of research findings. In December we will launch the second research capacity strengthening call for proposals.

To reflect and look towards the future, the second 5-year audit will take place in 2024, focusing on the selecting cycle, capacity strengthening activities and partnerships.

We aim to further increase the visibility and reach of LRI activities through strengthening internal and external communication and engagement with researchers, Partners and other stakeholders. We will follow up recommendations from the impact assessment to better support, monitor and share impact from the funded projects.

Lastly, we also look forward to our ongoing collaboration with the Global Partnership for Zero Leprosy's research pillar on the implementation of the global research agenda in our joint goal to promote and facilitate high-quality leprosy research.

10 OUR PARTNERS IN 2023

In 2023, the Leprosy Research Initiative comprised the following Partners:



We are grateful to the additional financial support that is provided to the Leprosy Research Initiative by the following organisations:



Interested to become a Partner of LRI and contribute to boosting scientific research in leprosy?
Contact us at info@leprosyresearch.org

11 OUR TEAM IN 2023

11.1 EXECUTIVES GROUP

Ms Linda Hummel	CEO, NLR (Chair)
Mr Joachim Beringer	CEO, GLRA
Mr Brent Morgan	Director, TLMI
Mr Bill Simmons	President/CEO, ALM
Mr Iñigo Laso	Director General, Anesvad Foundation

11.2 STEERING COMMITTEE

Dr David Scollard	Former Director of the US National Hansen's Disease Programs (Chair)
Dr Wim H. van Brakel	Medical Director, NLR
Dr Peter Steinmann	Public Health Specialist and Epidemiologist, Swiss Tropical and Public Health Institute
Dr Christa Kasang	Research Coordinator, GLRA
Ms Jannine Ebenso	Head of Quality Assurance, TLMI
Dr Sunil Anand	Regional Director for Asia, ALM
Dr Lucrecia Acosta Soto	Associate Professor, University of Michael Hernandez de Elche
Ms Arantzazu Quintana / Ms Marlen Eizaguirre	International Cooperation / Research, Anesvad Foundation

11.3 SCIENTIFIC REVIEW COMMITTEE

Dr Richard W. Truman (Chair)	Former Chief of the Laboratory Research Branch of the National Hansen's Disease Program / Principal Investigator of the Leprosy Research Support program of the National Institutes of Allergy and Infectious Disease, USA
Dr Jos H.M. Dekker	Rehabilitation Physician (retired), Heliomare Rehabilitation Centre at Red Cross Hospital, the Netherlands
Dr Bassey E. Ebenso (until April)	Lecturer in International Public Health, Leeds University, Institute of Health
Prof. Dr Françoise Portaels	Professor Emeritus, Institute of Tropical Medicine Antwerp, Belgium
Prof. Dr Patricia D. Deps	Full Professor and Head of the Department of Social Medicine, Postgraduate Programme in Infectious Diseases, Federal University of Espirito Santo, Brazil
Prof. Paul Fine	Professor Emeritus of Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, United Kingdom
Dr Zoica Bakirtzief	Adjunct Associate Professor (External Professor), Psychology Department, Federal University of Santa Maria, Brazil
Dr Ad P. Koets	Senior Scientist and Head of the National Reference Laboratory for Mycobacterial Infections and Tuberculosis at Wageningen Bioveterinary Research (WBVR), the Netherlands
Dr Vanaja Shetty (from April)	Director / Senior Scientist (retired) The Foundation For Medical Research, India
Dr Cassandra White (from September)	Associate Professor of Anthropology, Department of Anthropology, Georgia State University

11.4 LRI COMMUNICATIONS COMMITTEE (COCO)

Mr Stephen Labib	International Communication Advisor, NLR
Mr Guillermo Maceiras	Strategic communication, Anesvad Foundation
Ms Sarah Hesshaus	Vice President of Business Process & Communications, ALM
Ms Jessica Mussro	Communications Manager, ALM
Mr Tim Burton	Global Communications Lead, TLMI
Mr Subhojit Goswami	Senior Program Manager - Advocacy & Communications, TLM India
Ms Johanna Schultheiß	Press and Public Relations Officer, GLRA

11.5 LRI SECRETARIAT

Dr Suzan Trienekens	Coordinator
Ms Nicole Dinnissen	Programme Officer
Ms Chrysa Menexi	Support Officer

12 REVIEWER ACKNOWLEDGEMENTS

We would like to thank all our external reviewers who dedicated their time to the peer review of the full proposals in 2023:

**ELIANE IGNOTTI
MIRJAM BAKKER
LAURA GILLINI
PEMMARAJU RAO
ERIC WAN
MARIA PENA
RAMANUJ LAHIRI
KIM HARTOG
ABHIJIT NADKARNI
DEANNA HAGGE
WILLIAM FABER
ERWIN SCHURR
TOM GILLIS
JOHN CHANGALUCHA
EPCO HASKER
WIM BRANDSMA
HUIB CORNIELJE
GAIL DAVEY**

**LINDA ADAMS
GERALDO PEREIRA
MILENA SIMIC
KERSTIN BEISE
MAVIS DAKO-GYEKE
GIDADO MUSTAPHA
JOSÉ POSTIGO
LANCE WALLER
MELISSA EDMISTON
TOM HAMBRIDGE
NIENKE VELDHUIJZEN
INDRA NAPIT
SHYAMALA ANAND
ANOUK VAN HOOIJ
MEDHI DENISA ALINDA
RIE YOTSU
CLAIRE FULLER
MAYA SEMRAU**

13 FINANCIAL NARRATIVE

Summary Budget LRI 2024

	Budget 2024	Actuals 2023
Income:		
Income from contributors	1,101,000	1,130,988
Other income	573,000	263,880
Income in return of goods and services	69,000	37,011
Sum of income	1,743,000	1,431,879
Expenses:		
Project costs	1,988,000	1,234,262
Running costs	298,000	252,136
Sum of expenses	2,286,000	1,486,398
Result	-543,000	-54,519

Financial results 2023

In 2023 LRI received a total contribution from partners of €1,130,988 and in addition to this an amount of €263,880 was received from co-funding partners towards specific research projects and running costs. The freely available funds consist of cash held in the bank account and amount to €587,291 as per 31 December 2023.

The total expenses arrived at €1,486,398. The deficit of 2023 amounting to €54,519 is withdrawn from the earmarked reserves of LRI. This decreased the total earmarked reserves from

€1,395,901 to €1,341,382. The earmarked reserves are formed in accordance with LRI policy, please refer to the section notes accompanying the annual accounts for 2023 for further clarification.

Outlook 2024

LRI will receive a contribution of €1,101,000 from partners, an amount of €573,000 for co-financed projects and an amount of €69,000 in return of goods and services. Looking forward, we expect the expenditures to increase to €2,286,000 due to an expected increase in project activities.

14 ANNUAL ACCOUNTS

Amsterdam, the Netherlands

Date: 26 June 2024

CONTENTS

I. Balance sheet as at 31 December 2023	19
II. Statement of Income and Expenses 2023	20
III a. Notes accompanying the Annual Accounts 2023	21
III b. Notes to Balance sheet 2023	23
III c. Notes to the Income and Expenditure 2023	25
IV Independent auditor's report	28
V Annexes	29
annex V.1 Overview of research projects	30
annex V.2 Budget LRI 2023	31
annex V.3 Multi Annual Budget LRI 2023-2025	32
annex V.4 Board and Executives Group of LRI	33

I. BALANCE SHEET AS AT 31 DECEMBER 2023

amounts in €

Notes		31 December 2023	31 December 2022
	Assets		
2.	Current assets		
	Accounts receivable	125,641	-
	Balances and accounts from NLR	960,607	1,220,761
	Paid in advance	2,345	-
	LRI Amounts receivable	17,136	-
	Cash and cash equivalents	<u>587,291</u>	<u>744,922</u>
	Total assets	<u>1,693,020</u>	<u>1,965,683</u>
	Liabilities		
3.	Reserves		
	Earmarked reserves	<u>1,341,382</u>	<u>1,395,901</u>
		1,341,382	1,395,901
4.	Short-term liabilities		
	Other payables	<u>351,638</u>	<u>569,782</u>
	Total liabilities	<u>1,693,020</u>	<u>1,965,683</u>

II. STATEMENT OF INCOME AND EXPENSES 2023

amounts in €

Notes	Actuals 2023	Budget 2023	Actuals 2022
5. Income			
Income from contributors	1,130,988	1,133,000	1,179,000
Other income	263,880	523,000	249,169
Income in return of goods and services	37,011	15,000	15,477
Total income	1,431,879	1,671,000	1,443,646
6. Expenses			
Project costs	1,234,262	2,009,000	1,411,106
Staff costs, housing and office costs	226,283	222,000	227,529
Other operating expenses	25,853	37,000	26,204
Total expenses	1,486,398	2,268,000	1,664,839
Result of income and expenses	-54,519	-597,000	-221,193

III A. NOTES ACCOMPANYING THE ANNUAL ACCOUNTS 2023

General and accounting policies

These are the annual accounts of 2023 of the Leprosy Research Initiative (LRI). LRI has been registered since June 1st 2015 as a foundation under Dutch law. These are the annual accounts of LRI presented for the year 2023, which started on January 1st and ended December 31st. LRI is registered at the Chamber of Commerce no. 63431874.

General note on the accounting policies

The annual accounts have been prepared in accordance with Guideline C for small non-profit organisations (Dutch: Richtlijn C1 Kleine organisaties zonder winststreven) as published by the Dutch Accounting Standards Board (Raad voor de Jaarverslaggeving) and revised in 2023.

Activities

The LRI is a leprosy research funding and capacity strengthening organisation. Partners of the LRI contribute to a joint fund which is managed by the LRI and reserved for research that is exclusively or strongly related to leprosy. An efficient, transparent and scientifically sound and rigorous selection process was developed for the selection of research proposals as well as a scientifically high-quality monitoring mechanism of research projects. A comprehensive explanation of our mission and goals and a detailed account of the content of our work can be found in our annual report.

The LRI work proceedings and work activities.

The LRI fully delegated all its work proceedings and activities to NLR. The Supervisory Board of NLR supervises the proceedings and activities as reported by the NLR Director.

Registered address

The registered and actual address of the LRI is Wibautstraat 137k, 1097 DN in Amsterdam, the Netherlands.

Accounting period

The annual accounts have been drawn up for an accounting period of one year. The financial year is equal to the calendar year. The annual accounts have been prepared on a historical cost basis of accounting.

Accounting policies for the valuation of assets and liabilities and the determination of the result

All amounts in the annual accounts are in € or a multiple of €1,000 or rounded to the nearest amount in €. The amounts are compared to the part for research activities and objectives from the formal LRI budget for 2023 (approved by the Supervisory Board in December 2022).

The annual accounts have been prepared in accordance with the principle of continuity.

Income from funding and the allocation of funds

Each LRI full partner has committed an annual contribution to the LRI joint fund for research projects and contributes an equal share to LRI running costs. Associate partners and co-financiers contribute to specific projects and/or to the running costs. The income from full partners, associate partners and co-financiers are recognised in the year to which the item of income relates and are allocated to the year in question on an actual cost basis. The income is shown gross, before any deduction of associated costs, unless otherwise stated. Necessary costs to realise certain benefits, are presented in the statement of income and expenses as expense.

Grant commitments

The grant commitments are recognised as conditional commitments. The LRI receives from the grantees two progress reports annually, including scientific progress regarding the research project and financial statements: a semi-annual report and an annual report. The semi-annual report must be submitted each year on September 1st. The deadline for submission of the annual report is March 1st.

The amounts that are expected to be settled in future years and are accounted for, insofar as expenditures are appropriate within the condition, are included as short-term liabilities. The LRI does not hold any long-term liabilities.

Accounts receivable

Receivables are initially valued at the fair value of the consideration to be received, including transaction costs if material.

Cash and cash equivalents

Cash and cash equivalents include cash and bank balances represent the balance of the bank account held for the Secretariat of the LRI, in the Netherlands and are immediately accessible. The LRI does not have any borrowings or loans. The LRI does not invest, nor does it make use of any financial instruments.

General note on the balance sheet and statement of income and expenses

In general, assets and liabilities are stated at the amounts at which they were acquired or incurred, or current value. If not specifically stated otherwise, they are recognised at the amounts at which they were acquired or incurred. The balance sheet and statement of income and expenses include references to the notes. Notes to the line items of the balance sheet and the statement of income and expenses have been numbered in the financial statements.

Foreign currency

The annual accounts are presented in €. Transactions in foreign currency are converted to € at the exchange rate of the transaction date.

Reserves

The LRI ensures that contributions are used for the intended cause. If more funds are allocated to a

specific research project than the reported expenditure in that particular year for that project, the LRI will allocate the surplus amount to the same project in the remaining grant period. If, upon completion, the actual expenditures of a specific project are lower than the grant awarded, the remaining budget will be deposited in the joint fund. The (earmarked) reserves are the result of income and expenses and are held in accordance with budgets for grant awards and for the running costs of the LRI for future years.

Reserves and investments

The result of 2023 is withdrawn from the earmarked reserves. The earmarked reserves are used for active and new grant awards as well as running costs to ensure the sustainability of the LRI with a horizon of three years. The LRI holds no investments.

Management of the LRI and remuneration of Supervisory Board and Executives Group

The LRI is managed by the Director of NLR, implementing the decisions of the LRI Executives Group and supervised by the Supervisory Board of NLR. No remuneration was paid to the Supervisory Board members and Director of NLR, and no loans, advances or guarantees were given.

Events after the reporting period

In these accounts no significant events after the reporting period occurred which should be included.

Publication

This report is available on www.leprosyresearch.org. The 2023 annual report and the annual accounts are available in a digital format primarily for environmental reasons. A (free of charge) printed copy can be obtained on request.

III B. NOTES TO BALANCE SHEET 2023

In the notes to the balance sheet variances between 2022 and 2023 are elaborated upon further.

1. Tangible fixed assets

Tangible fixed assets are used for the main activities and entirely held for operational management. The LRI holds no tangible fixed assets and therefore this is not valued in 2022 and 2023.

2. Current assets

This item includes all receivables which are due within one year, amounts paid in advance and cash and cash equivalents.

	31 December 2023	31 December 2022
	€	€
Accounts receivables	125,641	-
Balances and accounts from NLR	960,607	1,220,761
Paid in advance	2,345	-
LRI amounts receivable	17,136	-
Cash and cash equivalents	587,291	744,922
	<u>1,693,020</u>	<u>1,965,683</u>

The income from contributions is accounted for once the commitment has been confirmed. Other accounts receivables includes €125,641 as contributions to be received. The item Balances and accounts from NLR relates to the receivable funds from NLR. This amount is expected but not yet received income and consists of an amount of €1 million which has been temporarily deposited in the account of NLR as part of LRI's cash management and is freely available to LRI. The remainder of the total amount under item Balances and accounts from NLR comprises the contribution of NLR towards LRI and the paid in advance staff costs; these costs between LRI and NLR were settled in 2023. The item paid in advance is Flexi-Grant® Annual Licence Fee till May 2024 (paid in 2023). The item LRI amounts receivable relates to the Q4 2023 Anesvad contribution. Cash and cash equivalents are cash and bank balances in € in the Netherlands held by the LRI office in Amsterdam. The LRI holds its main current account at ING Bank (NL) The cash and cash equivalents balance at ING Bank for the year ended December 31st 2023 is €587,291. The balance of cash and cash equivalents are available immediately.

3. Reserves

The LRI ensures that contributions are used for the intended cause. If more funds are allocated to a specific research project than the reported expenditure in that particular year for that project, the LRI will allocate the surplus amount to the same project in the remaining grant period. If, upon completion, the actual expenditures of a specific project are lower than the grant award, the remaining budget will be deposited in the joint fund. The (earmarked) reserves are the result of income and expenses and are held in accordance with budgets for grant awards and for the running costs of the LRI for future years.

The LRI's reserves are as follows:

	31 December 2023	31 December 2022
	in €	in €
Earmarked reserves	1,341,382	1,395,901
	<u>1,341,382</u>	<u>1,395,901</u>

General notes on the reserves

- For the budget of 2023, a deficit of €597,000 was accounted. Several of the research projects have experienced delay in progress due to COVID-19 related challenges as well as general research process challenges such as extensive ethical approval procedures. Following review by the Scientific Review Committee, the LRI Executives Group has accepted requests from projects for no-cost extensions to continue activities related to the grant award.

The negative result of 2023 arrived at €54,519 and is withdrawn from the earmarked reserves of the LRI.

- While partners contribute to the joint fund, associated partners and co-financers contribute to specific projects. Some of the funds received in 2023 for specific projects remained unspent. These have been re-allocated to the 2024 budget.
- The LRI holds no continuity reserve.

	Earmarked reserves	Total
	in €	in €
Balance as per 1 January 2023	1,395,901	1,395,901
- Movements	-	-
- Withdrawals and additions	-54,519	-54,519
Balance as per 31 December 2023	<u>1,341,382</u>	<u>1,341,382</u>

4. Short term liabilities

All current liabilities fall due in maximum four years from date of signature. The fair value of the current liabilities approximates the book value due to its short-term character.

Other payables	31 December 2023	31 December 2022
	in €	in €
Other payables	351,638	569,782
	<u>351,638</u>	<u>569,782</u>

Other payables are mainly amounts payable for audit and project costs, not yet invoiced in 2023. The amounts received in advance (€347,527) are also calculated under this item, which are unspent funds from contributors towards research projects.

Commitments not included in the balance sheet

The LRI had made commitments for running research projects for a total value of €1,171,778. The total budgeted project costs for the years 2024-2026 are €4,325,000. (see annex 3 for details).

Events after balance sheet date

No events have occurred between the balance sheet date and the date on which the Supervisory Board adopted the annual accounts, which would affect the 2023 annual accounts or the condition of LRI at the end of the financial year or thereafter.

III C. NOTES TO THE INCOME AND EXPENDITURE 2023

5. Income

Each LRI full partner has committed an annual contribution of a minimum of €100,000 to the joint LRI research fund and contributes an equal share to the LRI running costs. In 2023 the full partners were: American Leprosy Missions (ALM), German Leprosy and Tuberculosis Relief Association (GLRA/DAHAW), The Leprosy Mission (TLM) International, Anesvad Foundation, and NLR. Associate partners, in 2023 these were Damien Foundation and Effect Hope, contribute a chosen contribution less than €100,000 to the joint fund and no contribution to the running costs. The breakdown of the total income is as follows:

	Actuals 2023	Budget 2023	Actuals 2022
	in €	in €	in €
<i>Income from allied and joint non-profit organisations</i>			
ALM	173,970	174,000	168,000
GLRA/DAHAW	194,000	194,000	188,000
TLM International	144,000	144,000	138,000
Anesvad Foundation	200,000	200,000	200,000
NLR	350,000	350,000	350,000
Damien Foundation	35,000	35,000	135,000
Effect Hope	34,018	36,000	-
<i>Other income</i>			
Turing Foundation	208,711	426,000	155,756
Other amounts from partners	43,391	97,000	40,560
Other amounts	11,778	-	52,853
<i>Income in return of goods and services</i>			
Others	37,011	15,000	15,477
	1,431,879	1,671,000	1,443,646

The total amount of income available for allocation in line with the objectives for 2023 arrived at €1,431,879.

The actuals of the total income in 2023 was 14% lower than budgeted.

As per agreement, Turing Foundation contributed 5% of their co-funding on project funding towards running costs as realised at the end of the year 2023, resulting in a total contribution from Turing Foundation of €208,711 and received €11,778 for overhead. For 2023 we received an earmarked contribution of €43,391 from St Francis Leprosy Guild. The amount of €37,011 under the item Income and return of goods and services related to the contribution of the Global Partnership for Zero Leprosy (GPZL) towards salary cost of the LRI Coordinator for

consultancy, the LRI Spring Meeting registrations and the Contribution from Anesvad Foundation for expenses relating to the development of the new grant collaboration.

6. Expenses

Research

The expenses mainly consisted of funding of research projects cost in line with the active grant awards. A total of 39 research projects were funded in 2023. (see annex 1 for expense details by projects).

	Actuals 2023	Budget 2023	Actuals 2022
	in €	in €	in €
Research			
Project costs	1,234,262	2,009,000	1,411,106
	1,234,262	2,009,000	1,411,106

The LRI spent a total of €1,234,262 on project funding. The actual project costs were 61% of the budgeted project costs. The difference is mainly due to the requested and approved no-cost extensions for which instalments are transferred later than originally planned. For seven projects, no instalments were transferred in 2023 at all, with main reasons for delay being awaiting ethical approval to start implementation and extended project completion, resulting in putting the final instalment on hold. In addition, several newly granted projects started activities in the second half of 2023, while budget was estimated for the full calendar year.

Running costs

The LRI running costs consist of staff costs for the LRI Secretariat staff, housing expenses and other operating expenses that cannot be directly allocated to the projects. The actuals of staff costs were 2% higher than budgeted and the housing and office expenses of 2023 were in accordance with the budget, other operating expenses were almost 31% below budget.

	Realisation 2023	Budget 2023	Realisation 2022
	in €	in €	in €
Running costs			
Staff expenses	197,283	193,000	190,529
Housing expenses	20,000	20,000	20,000
Office expenses	9,000	9,000	17,000
Other operating expenses	25,853	37,000	26,204
	252,136	259,000	253,733

	Actuals 2023	Budget 2023	Actuals 2022
	in €	in €	in €
Staff expenses			
Wages and salaries	149.604	148.000	147.166
Social security costs	24.345	26.000	25.556
Pension contributions	16.471	17.000	17.434
Other personnel costs	6.863	2.000	373
	197.283	193.000	190.529

TOTAL EXPENSES	1,486,398	2,268,000	1,664,839
TOTAL INCOME	1,431,879	1,671,000	1,443,646
RESULT	-54,519	-597,000	-221,193

In 2023 on average 2.6 FTEs (2022: 2.7 FTEs) were employed in the Secretariat of the LRI in Amsterdam. The LRI had no staff employed abroad during 2023.

The LRI has no staff members on its payroll; all staff is employed by NLR and the expenditure is charged to the LRI. For the LRI Secretariat staff, the NLR standard terms, benefits, and conditions of employment apply. The total staff costs of the LRI for 2023 amount to €197,283 and consist of wages and salaries, pension costs (insured with Pensioenfonds Zorg en Welzijn), social security charges and other personnel costs.

GPZL contributed €16,751 towards staff costs for 2023; this amount is according the classification presented under the item Income in return of goods and services (note 5).

IV INDEPENDENT AUDITOR'S REPORT

INDEPENDENT AUDITOR'S REPORT

To: the Supervisory Board and the management of
Stichting Leprosy Research Initiative.

A. Report on the audit of the financial statements 2023 included in the annual report.

Our opinion

We have audited the financial statements 2023 of Stichting Leprosy Research Initiative based in Amsterdam, the Netherlands.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of Stichting Leprosy Research Initiative at 31 December 2023 and of its result for 2023 in accordance with the 'RJ-Richtlijn C1 Kleine organisaties zonder winststreven' (Guideline for annual reporting C1 'Small not-for-profit organisations') of the Dutch Accounting Standards Board) .

The financial statements comprise:

1. the balance sheet as at 31 December 2023;
2. the statement of income and expenses for 2023; and
3. the notes comprising of a summary of the accounting policies and other explanatory information.

Basis for our opinion

We conducted our audit in accordance with Dutch law, including the Dutch Standards on Auditing. Our responsibilities under those standards are further described in the 'Our responsibilities for the audit of the financial statements' section of our report.

We are independent of Stichting Leprosy Research Initiative in accordance with the Verordening inzake de onafhankelijkheid van accountants bij assurance-opdrachten (ViO, Code of Ethics for Professional Accountants, a regulation with respect to independence) and other relevant independence regulations in the Netherlands. Furthermore we have complied with the Verordening gedrags- en beroepsregels accountants (VGBA, Dutch Code of Ethics).

We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Wamberg Offices
Wamberg 37
1083 CW Amsterdam
Telefoon 020 571 23 45

E-mail info@dubois.nl
www.dubois.nl
KvK nummer 34374865



B. Report on the other information included in the annual report.

The annual report contains other information, in addition to the financial statements and our auditor's report thereon.

The other information consists of:

- the Management Board's report;
- Annex V-1: Overview of projects ongoing in 2023;
- Annex V-2: Budget LRI 2024;
- Annex V-3: Multi Annual Budget LRI 2024-2026;
- Annex V-4: Board and Executives Group of LRI

Based on the following procedures performed, we conclude that the other information is consistent with the financial statements and does not contain material misstatements.

We have read the other information. Based on our knowledge and understanding obtained through our audit of the financial statements or otherwise, we have considered whether the other information contains material misstatements.

By performing these procedures, we comply with the requirements of the Dutch Standard 720. The scope of the procedures performed is substantially less than the scope of those performed in our audit of the financial statements.

Management is responsible for the preparation of the other information, including the Management Board's report in accordance with Guideline for annual reporting 'RJ-Richtlijn C1 Kleine organisaties zonder winststreven' (Guideline for annual reporting C1 'Small not-for-profit organisations').

C. Description of responsibilities regarding the financial statements

Responsibilities of the Supervisory Board and the management for the financial statements.

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Guideline for annual reporting 'RJ-Richtlijn C1 Kleine organisaties zonder winststreven' (Guideline for annual reporting C1 'Small not-for-profit organisations'). Furthermore, management is responsible for such internal control as management determines is necessary to enable the preparation of the financial statements that are free from material misstatement, whether due to fraud or error.

As part of the preparation of the financial statements, management is responsible for assessing the foundation's ability to continue as a going concern. Based on the financial reporting framework mentioned, management should prepare the financial statements using the going concern basis of accounting, unless management either intends to dissolve the foundation or to cease operations, or has no realistic alternative but to do so.

Management should disclose events and circumstances that may cast significant doubt on the foundation's ability to continue as a going concern in the financial statements.

The supervisory board is responsible for overseeing the organisation's financial reporting process.

Our responsibilities for the audit of the financial statements

Our objective is to plan and perform the audit engagement in a manner that allows us to obtain sufficient and appropriate audit evidence for our opinion.

Our audit has been performed with a high, but not absolute, level of assurance, which means we may not detect all material errors and fraud during our audit.

Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements. The materiality affects the nature, timing and extent of our audit procedures and the evaluation of the effect of identified misstatements on our opinion.

We have exercised professional judgement and have maintained professional skepticism throughout the audit, in accordance with Dutch Standards on Auditing, ethical requirements and independence requirements.

Our audit included among others:

- identifying and assessing the risks of material misstatement of the financial statements, whether due to fraud or error, designing and performing audit procedures responsive to those risks, and obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
- obtaining an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control;
- evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- concluding on the appropriateness of management's use of the going concern basis of accounting, and based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a foundation to cease to continue as a going concern.
- evaluating the overall presentation, structure and content of the financial statements, including the disclosures; and
- evaluating whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the Supervisory Board and the management regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant findings in internal control that we identify during our audit.

Amsterdam, 28 June 2024

Dubois & Co. Registeraccountants

A.P. Buteijn RA

A. Koek RA

V ANNEXES

annex V-1 Overview of projects ongoing in 2023

Project no.	Project title	Actuals 2023	Budget 2023
703.15.41	TLM Nepal/Helminth influences in leprosy	0	20,000
704.16.71	ENLIST MTX - two randomised controlled trials in ENL	0	249,591
706.18.39	PUCPR/Functional analysis of candidate variants in the early-onset leprosy phenotype using novel cellular model	0	0
707.19.02	Erasmus MC/Monitoring effect of prophylactic interventions, Bangladesh	22,500	22,500
707.19.20	UGM/Implementation Dapsone Hypersensitivity Syndrome, Indonesia/ Nepal	22,718	40,690
707.19.45	DF Bangladesh/Assessing the effectiveness of IECs, Bangladesh	24,517	62,149
707.19.60	GLRA - NLTB/Collaboration traditional healers, Sierra Leone	12,776	30,751
707.19.62	Nagasaki University/Integrated approach skin camp, eSkin Health app, Côte d'Ivoire	5,226	0
707.19.21	BLP/Clofazimine for MB cases at high risk of ENL, Bangladesh/India	14,462	27,644
707.19.64	ALM/LepVax	0	82,500
708.20.04	Oxford Univ./Efficacy and Tolerability of Adjunct Metformin in Multidrug Treatment, Indonesia	54,836	54,836
708.20.09	ICMR/Molecular Mechanisms of Immunomodulation Imparted by MIP vaccine	0	70,888
708.20.12	VU/Informing (generic) approaches to reduce stigma	37,714	37,714
708.20.14	NIMR/Leprosy Antimicrobial Resistance Surveillance in PEP Setting, Tanzania (LARS)	37,422	37,422
708.20.15	GLRA Nigeria/Improving mental health&Quality of Life of Persons affected by Leprosy or Buruli ulcer	24,666	47,849
708.20.17	ENAPAL/Assessing long-term outcomes & sustainability of family-based approaches, Ethiopia	36,858	42,438
FP21.17	ALM/Assessing Electronic Data Collection Tools, Pathways and HMIS Integration	13,289	35,079
FP21.8	NHDP/The Use of Molecular Methods in Subclinical Murine Models of Leprosy	14,248	14,248
FP21.14	VU/Improving management of leprosy reactions and quality of life of persons affected	0	8,411
FP21.20	NLR IO/Testing an App supported delivery system for Leprosy Post Exposure Prophylaxis (PEP) services	0	64,085
FP21.10	LUMC/Point-of-care immunodiagnostic tests	74,832	74,831
FP21.26	Effect Hope/Exploring strategies and identifying effective mechanism, Cote d'Ivoire	21,682	34,079
FP22.17	TLM Trust India/Comparison of removable device & total contact cast for healing of ulcer	20,272	20,272
FP22.6	TLM Niger/Understanding & Reducing Leprosy-Related Stigma Among Healthcare Workers, Niger	49,988	49,988
FP22.21	PLF/COMBINE: Leprosy elimination by community screening & mass chemoprophylaxis, Kiribati	50,023	50,024
FP22.9	RH-MUHC/Identifying drug targets to treat leprosy reactions via genetic susceptibility factors	93,646	69,646
FP22.19	NLR Nepal/How effective is ongoing SDR-PEP implementation under routine programme conditions	44,976	44,976
FP22.15	RedAid Nigeria/Audio & written interventions to improve the perception, knowledge & attitudes towards leprosy	73,020	73,020
FP22.8	Erasmus MC/Endgame strategy for leprosy in the Maldives: optimal targeting of PEP	20,871	25,752
FP23.100016	ICDDR,B/Evaluation of Mycobacterium leprae specific RPA assay	34,730	43,316
FP23.100013	Erasmus MC/Leprosy incidence, clustering and risk factors	42,912	47,680
FP23.100011	NRC-Myc/Setting an EQA programme for enhancing capacity building	23,000	39,000
FP23.100019	TLM Trust India/Addressing healing after multi-drug treatment	37,600	41,619
FP23.100017	ICMT/Evaluation of five transcriptomic biomarkers for leprosy	87,788	87,788
FP23.100009	ALM/The role of persons affected as agents of change in their community	32,538	37,862
FP23.100004	NLR India/Compassion training for reducing stigma & improving quality of care	27,752	63,249
FP23.100018	Lepira India/Personalised footwear for foot ulcers in leprosy by baropodometry	76,548	86,672
FP23_CS.6	LTRV/Collaborative co-design to optimize evidence-based and contextual general health worker training	8,199	12,500
FP23_CS.5	INF/Theomographic assessment of autonomic innervation in Leprosy	3,535	12,500
Subtotal Research projects		1,145,144	1,863,569
706.18.99	Workshops	1,308	34,000
709.00.20	SRCLRI spring & autumn meetings	86,212	100,000
709.00.21	Publication costs	0	9,000
709.00.23	Internships	1,598	3,000
Subtotal Other projects		89,118	146,000
Total projects		1,234,262	2,009,569

annex V-2

Budget LRI 2024

amounts x €1,000

	Budget 2024	Actuals 2023	Budget 2023
Income			
Income from contributors			
ALM	144	174	174
GLRA/DAHW	194	194	194
TLM International	144	144	144
Anesvad Foundation	200	200	200
NLR	350	350	350
Damien Foundation	35	35	35
Effect Hope	34	34	36
Other income			
Turing Foundation	467	220	426
Income for co-financed projects	106	43	97
Income in return of goods and services	69	37	15
Sum of income	1,743	1,431	1,671
Expenses			
Project costs (ongoing)	1,988	1,234	2,009
	1,988	1,234	2,009
Running costs	298	252	259
	298	252	259
Sum of expenses	2,286	1,486	2,268
Result	-543	-55	-597

annex V-3

Multi Annual Budget LRI 2024-2026

amounts x €1,000

	Budget 2024	Projection 2025	Projection 2026
Income:			
Income from contributors	1,101	1,109	1,121
Other income	573	550	546
Income in return of goods and services	69	69	69
Sum of income	1,743	1,728	1,736
Expenses:			
Approved projects (ongoing)	1,988	1,420	917
	1,988	1,420	917
Running costs	298	313	330
	298	313	330
Sum of expenses	2,286	1,733	1,247
Result	-543	-5	489

annex V-4 Board and Executives Group of LRI

Board of Directors

	From	Until
Nederlandse Stichting voor Leprabestrijding	01/06/2015	-

Executives Group

The LRI Executives Group (EG) consists of the Executive Directors of the LRI partners.

Ms L. Hummel

Chief Executive Officer; NLR (Chair) 01/01/2021

Mr B. Simmons

President/Chief Executive Officer; American Leprosy Missions

Mr J. Beringer

Chief Executive Officer; German Leprosy Relief Association

Mr B. Morgan

Director; The Leprosy Mission International

Mr I. Lasa

General Director; Anesvad Foundation



LEPROSY RESEARCH INITIATIVE

COLOPHON

Publication: June 2024

The Annual Report of the Leprosy Research Initiative is published on: leprosyresearch.org/about-us/achievements

Cover photo: Health education for persons affected by leprosy and their family members in Debre Work, Ethiopia from project *“Assessing the effectiveness of family-based approaches aimed at prevention and sustainable self-management of disabilities, impacting the quality of life, mental wellbeing and participation of people with leprosy, podoconiosis and lymphatic filariasis and their families in the Amhara region, Ethiopia”*

Postal address:
P.O. Box 95005
1090 HA Amsterdam
The Netherlands

Visiting address:
Wibautstraat 137k
1097 DN Amsterdam
The Netherlands

Web:
www.leprosyresearch.org
Email:
info@leprosyresearch.org